Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 2
1944 1
1945 1
1948 1
1951 1
1954 1
1956 1
1957 1
1959 1
1960 2
1961 1
1962 6
1963 7
1964 1
1965 1
1966 2
1967 3
1968 3
1969 5
1970 2
1971 5
1972 13
1973 12
1974 8
1975 5
1976 6
1977 6
1978 11
1979 5
1980 11
1981 14
1982 21
1983 18
1984 23
1985 34
1986 23
1987 28
1988 22
1989 16
1990 26
1991 26
1992 25
1993 34
1994 31
1995 46
1996 48
1997 49
1998 43
1999 57
2000 58
2001 73
2002 124
2003 142
2004 139
2005 166
2006 194
2007 212
2008 206
2009 219
2010 248
2011 301
2012 305
2013 366
2014 381
2015 377
2016 345
2017 343
2018 343
2019 346
2020 393
2021 448
2022 449
2023 368
2024 130

Text availability

Article attribute

Article type

Publication date

Search Results

6,602 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: lin cc. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis.
Cho MG, Kumar RJ, Lin CC, Boyer JA, Shahir JA, Fagan-Solis K, Simpson DA, Fan C, Foster CE, Goddard AM, Lerner LM, Ellington SW, Wang Q, Wang Y, Ho AY, Liu P, Perou CM, Zhang Q, McGinty RK, Purvis JE, Gupta GP. Cho MG, et al. Among authors: lin cc. Nature. 2024 Jan;625(7995):585-592. doi: 10.1038/s41586-023-06889-6. Epub 2024 Jan 10. Nature. 2024. PMID: 38200309 Free PMC article.
Recommendations for terminology and the identification of neuropathic pain in people with spine-related leg pain. Outcomes from the NeuPSIG working group.
Schmid AB, Tampin B, Baron R, Finnerup NB, Hansson P, Hietaharju A, Konstantinou K, Lin CC, Markman J, Price C, Smith BH, Slater H. Schmid AB, et al. Among authors: lin cc. Pain. 2023 Aug 1;164(8):1693-1704. doi: 10.1097/j.pain.0000000000002919. Epub 2023 May 25. Pain. 2023. PMID: 37235637 Free PMC article.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Brose MS, et al. Among authors: lin cc. Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19. Cancer. 2022. PMID: 36259380 Free PMC article. Clinical Trial.
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY, Tsai XC, Lin CC, Tien FM, Kuo YY, Lee WH, Peng YL, Liu MC, Tseng MH, Hsu CA, Chen JC, Lin LI, Sun HI, Chuang YK, Ko BS, Tang JL, Yao M, Chou WC, Hou HA, Tien HF. Lo MY, et al. Among authors: lin cc. Am J Hematol. 2023 May;98(5):760-769. doi: 10.1002/ajh.26892. Epub 2023 Mar 13. Am J Hematol. 2023. PMID: 36861732
Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, Chung CS, Yen HH, Chou JW, Wong JM, Liu YH, Huang TY, Chuang CH, Tsai TJ, Chiang FF, Lu CY, Hsu WH, Yu FJ, Chao TH, Wu DC, Ho AS, Lin HH, Feng CL, Wu KL, Wong MW, Tung CC, Lin CC, Chen CC, Hu HM, Lu LS, Wang HS, Wu IC, Kuo HY, Wu JF, Yao Shih H, Ni YH, Tang SL, Chen PH, Wei SC. Lin WC, et al. Among authors: lin cc. Inflamm Bowel Dis. 2023 Nov 2;29(11):1730-1740. doi: 10.1093/ibd/izac269. Inflamm Bowel Dis. 2023. PMID: 36626567 Free PMC article.
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Kelly WK, et al. Among authors: lin cc. Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. Cancer Discov. 2024. PMID: 37861461 Free PMC article.
6,602 results